L
Lisa Kays
Researcher at Eli Lilly and Company
Publications - 9
Citations - 591
Lisa Kays is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Vemurafenib & Dabrafenib. The author has an hindex of 7, co-authored 9 publications receiving 465 citations.
Papers
More filters
Journal ArticleDOI
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng,Henry James Robert,Michael Kaufman,Wei-Ping Lu,Bryan D. Smith,Subha Vogeti,Thomas J. Rutkoski,Scott C. Wise,Lawrence Chun,Youyan Zhang,Robert D. Van Horn,Tinggui Yin,Xiaoyi Zhang,Vipin Yadav,Shih-Hsun Chen,Xueqian Gong,Xiwen Ma,Yue Webster,Sean Buchanan,Igor Mochalkin,Lysiane Huber,Lisa Kays,Gregory P. Donoho,Jennie L. Walgren,Denis J. McCann,Phenil J. Patel,Ilaria Conti,Gregory D. Plowman,James J. Starling,Daniel L. Flynn +29 more
TL;DR: Biochemical and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRAF activities.
Journal ArticleDOI
Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
Sheng-Bin Peng,Xiaoyi Zhang,Donald C. Paul,Lisa Kays,Wendy H. Gough,Julie Stewart,Mark Uhlik,Qi Chen,Yu-Hua Hui,Maciej J. Zamek-Gliszczynski,John A. Wijsman,Kelly M. Credille,Liang Zeng Yan +12 more
TL;DR: A small cyclic peptide, LY2510924, which is a potent and selective CXCR4 antagonist currently in phase II clinical studies for cancer, showed dose-dependent inhibition of tumor growth in human xenograft models developed with non–Hodgkin lymphoma, renal cell carcinoma, lung, and colon cancer cells that express functional CX CR4.
Journal ArticleDOI
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
Henry James Robert,Michael Kaufman,Sheng-Bin Peng,Yu Mi Ahn,Timothy M. Caldwell,Lakshminarayana Vogeti,Hanumaiah Telikepalli,Wei-Ping Lu,Molly M. Hood,Thomas J. Rutkoski,Bryan D. Smith,Subha Vogeti,David Miller,Scott C. Wise,Lawrence Chun,Xiaoyi Zhang,Youyan Zhang,Lisa Kays,Philip Arthur Hipskind,Wrobleski Aaron D,Karen Lynn Lobb,Clay Julia Marie,Jeffrey Daniel Cohen,Jennie L. Walgren,Denis J. McCann,Phenil J. Patel,David K. Clawson,Sherry Guo,Danalyn Manglicmot,C. Groshong,Cheyenne Logan,James J. Starling,Daniel L. Flynn +32 more
TL;DR: Compound 13, a compound not only active against BRAF V600E but also wild type BRAF and CRAF, was selected on the basis of its superior in vitro and in vivo profile and is currently being evaluated in phase I clinical studies.
Journal ArticleDOI
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
Emiliano Calvo,Victor J. Chen,Mark S. Marshall,Ute Ohnmacht,Scott M. Hynes,Elizabeth Kumm,H. Bruce Diaz,Darlene S. Barnard,Farhana F. Merzoug,Lysiane Huber,Lisa Kays,Philip W. Iversen,Antonio Calles,Beatrice Voss,Aimee Bence Lin,Nicolas J. Dickgreber,Thomas Wehler,Martin Sebastian +17 more
TL;DR: LY2603618 administered in combination with pemetrexed and cisplatin demonstrated an acceptable safety profile and pharmacokinetic parameters that correlate with the maximal pharmacodynamic effect in nonclinical xenograft models were achieved at doses ≥240 mg.
Journal ArticleDOI
Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
Sheng-Bin Peng,Xiaoyi Zhang,Donald C. Paul,Lisa Kays,Ming Ye,Peter Edward Vaillancourt,Michele Dowless,Louis Stancato,Julie Stewart,Mark Uhlik,Haiyan Long,Shaoyou Chu,Victor H. Obungu +12 more
TL;DR: It is demonstrated that CXCR4 inhibition by LY2624587 has the potential for the treatment of human hematological malignancies.